Irvine, CA, United States of America

Dorla Mirejovsky

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 82(Granted Patents)


Company Filing History:


Years Active: 1988-2016

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Dorla Mirejovsky

Introduction

Dorla Mirejovsky is a notable inventor based in Irvine, CA, who has made significant contributions to the field of medical treatments, particularly in bladder cancer. With a total of 9 patents to his name, Mirejovsky's work focuses on therapeutic compositions that enhance treatment efficacy.

Latest Patents

Mirejovsky's latest patents include groundbreaking methods for bladder cancer treatment. These patents disclose therapeutic compositions that comprise an indoloquinone compound along with a formulation vehicle. The formulation vehicle is designed to improve the solubility and stability of the indoloquinone compound. Furthermore, the coating compositions can include agents that enhance the adhesion of the coating to the bladder wall during intravesical delivery, thereby improving treatment outcomes.

Career Highlights

Throughout his career, Dorla Mirejovsky has worked with prominent companies in the pharmaceutical industry, including Gensia Sicor Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop innovative solutions that address critical health challenges.

Collaborations

Mirejovsky has collaborated with various professionals in his field, including Liananingsih Tanudarma and Dilip R Ashtekar. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Dorla Mirejovsky's contributions to bladder cancer treatment through his innovative patents highlight his dedication to improving patient care. His work continues to influence the medical field and offers hope for more effective treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…